These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 28326014)

  • 21. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.
    Martínez-Cué C; Martínez P; Rueda N; Vidal R; García S; Vidal V; Corrales A; Montero JA; Pazos Á; Flórez J; Gasser R; Thomas AW; Honer M; Knoflach F; Trejo JL; Wettstein JG; Hernández MC
    J Neurosci; 2013 Feb; 33(9):3953-66. PubMed ID: 23447605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome.
    Gómez de Salazar M; Grau C; Ciruela F; Altafaj X
    Front Mol Neurosci; 2018; 11():226. PubMed ID: 30140203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of trisomic proteins in Down syndrome model systems.
    Spellman C; Ahmed MM; Dubach D; Gardiner KJ
    Gene; 2013 Jan; 512(2):219-25. PubMed ID: 23103828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpressed Down Syndrome Cell Adhesion Molecule (DSCAM) Deregulates P21-Activated Kinase (PAK) Activity in an In Vitro Neuronal Model of Down Syndrome: Consequences on Cell Process Formation and Extension.
    Pérez-Núñez R; Barraza N; Gonzalez-Jamett A; Cárdenas AM; Barnier JV; Caviedes P
    Neurotox Res; 2016 Jul; 30(1):76-87. PubMed ID: 26966010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome.
    Blanchard J; Bolognin S; Chohan MO; Rabe A; Iqbal K; Grundke-Iqbal I
    J Neuropathol Exp Neurol; 2011 Dec; 70(12):1070-9. PubMed ID: 22082658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Belichenko PV; Gall J; George L; Nosheny R; Maloney MT; Salehi A; Mobley WC
    Neurobiol Dis; 2012 Feb; 45(2):683-91. PubMed ID: 22062771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Uguagliati B; Bonasoni MP; Bartesaghi R; Guidi S
    Brain Pathol; 2019 May; 29(3):366-379. PubMed ID: 30325080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells.
    Rachubinski AL; Maclean KN; Evans JR; Bjugstad KB
    Exp Gerontol; 2012 Sep; 47(9):723-33. PubMed ID: 22776132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models.
    Galdzicki Z; Siarey R; Pearce R; Stoll J; Rapoport SI
    Brain Res Brain Res Rev; 2001 Apr; 35(2):115-45. PubMed ID: 11336779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prefrontal-hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability.
    Alemany-González M; Gener T; Nebot P; Vilademunt M; Dierssen M; Puig MV
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11788-11798. PubMed ID: 32393630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathways to cognitive deficits in Down syndrome.
    Sturgeon X; Le T; Ahmed MM; Gardiner KJ
    Prog Brain Res; 2012; 197():73-100. PubMed ID: 22541289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome.
    William CM; Saqran L; Stern MA; Chiang CL; Herrick SP; Rangwala A; Albers MW; Frosch MP; Hyman BT
    J Neurosci; 2017 Oct; 37(41):9880-9888. PubMed ID: 28899917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome.
    Block A; Ahmed MM; Dhanasekaran AR; Tong S; Gardiner KJ
    Biol Sex Differ; 2015; 6():24. PubMed ID: 26557979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome.
    Fernandez F; Trinidad JC; Blank M; Feng DD; Burlingame AL; Garner CC
    J Neurochem; 2009 Jul; 110(1):157-69. PubMed ID: 19453946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.
    Rueda Revilla N; Martínez-Cué C
    Antioxidants (Basel); 2020 Aug; 9(8):. PubMed ID: 32756318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
    Belichenko NP; Belichenko PV; Kleschevnikov AM; Salehi A; Reeves RH; Mobley WC
    J Neurosci; 2009 May; 29(18):5938-48. PubMed ID: 19420260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
    Stringer M; Goodlett CR; Roper RJ
    Mol Genet Genomic Med; 2017 Sep; 5(5):451-465. PubMed ID: 28944229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome.
    Pinto B; Morelli G; Rastogi M; Savardi A; Fumagalli A; Petretto A; Bartolucci M; Varea E; Catelani T; Contestabile A; Perlini LE; Cancedda L
    Neuron; 2020 Dec; 108(5):887-904.e12. PubMed ID: 33027640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons.
    Huo HQ; Qu ZY; Yuan F; Ma L; Yao L; Xu M; Hu Y; Ji J; Bhattacharyya A; Zhang SC; Liu Y
    Stem Cell Reports; 2018 Apr; 10(4):1251-1266. PubMed ID: 29526735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.